Tarsus Pharmaceuticals
Commercializes XDEMVY for Demodex blepharitis and develops additional eye-care and infectious-disease therapies.
$71.76
After-hours close−0.03 (−0.04%)
At close$71.79(−0.18%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$1.53 | — | — |
| Aug 2026 | −$0.19 | −$0.43 | −124.2% |
| May 2026 | −$0.40 | −$0.16 | +60.2% |
| Feb 2026 | −$0.10 | −$0.20 | −94.2% |
| Nov 2025 | −$0.35 | −$0.30 | +14.3% |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Oct 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | −$1.53 | — | — | $183.6M | — | — |
| Aug 6, 2026 | −$0.19 | −$0.43 | −124.2% | $169.7M | $173.9M | +2.5% |
| May 6, 2026 | −$0.40 | −$0.16 | +60.2% | $149.6M | $162.1M | +8.3% |
| Feb 23, 2026 | −$0.10 | −$0.20 | −94.2% | $144.6M | $151.7M | +4.9% |
| Nov 4, 2025 | −$0.35 | −$0.30 | +14.3% | $144.6M | $118.7M | −17.9% |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | ||||||
| Aug 6, 2025 | ||||||
| May 1, 2025 | ||||||
| Feb 25, 2025 | ||||||
| Nov 13, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 8, 2024 | ||||||
| Feb 27, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 9, 2023 | ||||||
| Mar 13, 2023 | ||||||
| Nov 9, 2022 | ||||||
| Aug 11, 2022 | ||||||
| May 10, 2022 | ||||||
| Mar 14, 2022 | ||||||
| Nov 9, 2021 | ||||||
| Aug 4, 2021 | ||||||
| May 11, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Nov 25, 2020 | ||||||
| Oct 16, 2020 | ||||||
| Mar 31, 2020 | ||||||
| Dec 31, 2019 | ||||||
| Sep 30, 2019 | ||||||
| Jun 30, 2018 | ||||||
| Mar 31, 2018 | ||||||